Navigation Links
A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression

BURLINGTON, Mass., May 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a greater effect on depressive symptoms than current treatments is one of the greatest unmet needs in patients with treatment-resistant depression (TRD)*, according to insights from surveyed psychiatrists in the United States and Europe as well as U.S. managed care organizations' (MCOs') pharmacy directors. Pharmacological treatment for TRD most typically involves switching, combining (two antidepressants from different classes) or augmenting (combining another agent with an antidepressant). The atypical antipsychotics Abilify (Bristol-Myers Squibb/Otsuka Pharmaceutical's aripiprazole) and Seroquel XR (AstraZeneca's quetiapine XR, generics in the United Kingdom and Germany) are two therapies approved as adjunct therapies to antidepressants in the U.S. and are also used in this patient population.


"Adjunctive treatment with atypical antipsychotics, though considered effective by thought-leaders, generally results in significant weight gain, and so emerging therapies could differentiate themselves in the marketplace by demonstrating both efficacy in TRD and by having a more tolerable weight gain profile," said Decision Resources Analyst Alana Simorellis , Ph.D.

The DecisionBase 2013 report entitled In the Crowded Antidepressant Market Space, What Are the Remaining Opportunities for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. This finding suggests that cost-sensitive payers consider efficacy improvements to be of greater value than improvements in tolerability.

Surveyed U.S. psychiatrists expect to prescribe Eli Lilly's emerging therapy edivoxetine to 25 percent of their patients with TRD. Decision Resources forecasts that edivoxetine will earn a U.S. patient share for TRD similar to surveyed psychiatrists' estimate by 2021, based on top-line results from Phase II/III trials of edivoxetine as an adjunct therapy to SSRIs and positive Phase II/III monotherapy results in patients with major depressive disorder.

Clinical data and the opinions of interviewed thought leaders indicate that, among emerging therapies profiled in the report, Eli Lilly's edivoxetine shows considerable promise as an adjunct to antidepressant therapy. Additionally, edivoxetine appears to offer a more favorable profile in terms of neurological side effects and risk of weight-gain relative to the atypical antipsychotics.

*The majority of physicians interviewed and surveyed by Decision Resources consider a patient "treatment-resistant" if depressive symptoms persist despite treatment with at least two different trials of antidepressant drugs from two different drug classes.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.




SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
2. Cancer drug shortages mean higher costs and greater risk for patients
3. New Report Details NCPA Efforts to Drive Greater Medication Adherence
4. Greater New York Dental Meeting and Inside Dental Technology Announce Collaboration 2013
5. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
6. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
7. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
8. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
9. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical ... for cardiovascular conditions via the inhalation route, today announced ... Australia . InCarda is planning to undertake ... in the first half of 2016. The ... in Adelaide and Melbourne.  In ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Trustify is proud to announce the success of the seventh ... organization dedicated to ending domestic violence. , Trustify and Becky’s Fund have joined forces ... of domestic violence. Trustify is also proud to announce the launch of the company’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, ... Tennessee to receive Gigabit Internet through a partnership this year with Aeneas Internet ... Henderson is an attractive destination for entrepreneurs who want to build a business. ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and ... believe that with innovative technologies and under the right circumstances, these practices can ... benefit of a dual-approach to his or her therapeutic sessions, as well as ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
Breaking Medicine News(10 mins):